Calendar

pharmadog

Week of Feb 2, 2026

Feb 4, 2026approval189d agoATROPINE SULFATE — FDA approvalATROPINE SULFATE

Sponsor: ACCORD HLTHCARE. Form: SOLUTION. Route: INTRAVENOUS

full page →ATROPINE SULFATE →fda approvals ↗

Feb 4, 2026approval189d agoCARBOPLATIN — FDA approvalOncotelic Therapeutics, Inc.

Sponsor: QILU PHARM HAINAN. Form: INJECTABLE. Route: INTRAVENOUS

full page →fda approvals ↗

Feb 5, 2026approval188d agoAZTREONAM — FDA approvalAZTREONAM

Sponsor: HIKMA. Form: INJECTABLE. Route: INJECTION

full page →AZTREONAM →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: SAGENT PHARMS INC. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: SAGENT PHARMS INC. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoNICOTINE POLACRILEX — FDA approvalPL Developments Copiague LLC

Sponsor: P AND L. Form: GUM, CHEWING. Route: BUCCAL

full page →fda approvals ↗

Feb 5, 2026approval188d agoNYSTATIN — FDA approvalActavis Mid Atlantic LLC

Sponsor: STERANCO HLTHCARE. Form: SUSPENSION. Route: ORAL

full page →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoBUMETANIDE — FDA approvalBUMETANIDE

Sponsor: MSN. Form: TABLET. Route: ORAL

full page →BUMETANIDE →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: EUGIA PHARMA SPECLTS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: EUGIA PHARMA SPECLTS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoPRUCALOPRIDE SUCCINATE — FDA approvalSpecGx LLC

Sponsor: TEVA PHARMS INC. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 5, 2026approval188d agoCARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA) — FDA approvalcarbidopa

Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

full page →carbidopa →fda approvals ↗

Feb 5, 2026approval188d agoMYQORZO (AFICAMTEN) — FDA approvalaficamten

Sponsor: CYTOKINETICS. Form: TABLET. Route: ORAL

full page →aficamten →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoHYDROCORTISONE SODIUM SUCCINATE — FDA approvalHYDROCORTISONE SODIUM SUCCINATE

Sponsor: APOTEX. Form: INJECTABLE. Route: INJECTION

full page →HYDROCORTISONE SODIUM SUCCINATE →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: NOVAST LABS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalExtrovis AG

Sponsor: NOVAST LABS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Feb 5, 2026approval188d agoZOLEDRONIC ACID — FDA approvalZOLEDRONIC ACID

Sponsor: GLAND. Form: INJECTABLE. Route: INTRAVENOUS

full page →ZOLEDRONIC ACID →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 5, 2026approval188d agoFLUOROURACIL — FDA approvalEfudex

Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

full page →Efudex →fda approvals ↗

Feb 6, 2026approval187d agoANAGRELIDE HYDROCHLORIDE — FDA approvalTakeda Pharmaceuticals USA Inc

Sponsor: BARR LABS. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

Feb 6, 2026approval187d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalFLUOXETINE HYDROCHLORIDE

Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗

Feb 6, 2026approval187d agoGLYCOPYRROLATE — FDA approvalFresenius Kabi USA LLC

Sponsor: PH HEALTH. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 6, 2026approval187d agoIDARUBICIN HYDROCHLORIDE — FDA approvalIDARUBICIN HYDROCHLORIDE

Sponsor: PFIZER. Form: SOLUTION. Route: INTRAVENOUS

full page →IDARUBICIN HYDROCHLORIDE →fda approvals ↗

Feb 6, 2026approval187d agoPRAVASTATIN SODIUM — FDA approvalSenores Pharmaceuticals Inc

Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 6, 2026approval187d agoTICAGRELOR — FDA approvalTICAGRELOR

Sponsor: MANKIND PHARMA. Form: TABLET. Route: ORAL

full page →TICAGRELOR →fda approvals ↗

Feb 6, 2026approval187d agoNOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approvalNOREPINEPHRINE BITARTRATE

Sponsor: BAXTER HLTHCARE CORP. Form: SOLUTION. Route: INTRAVENOUS

full page →NOREPINEPHRINE BITARTRATE →fda approvals ↗

Feb 6, 2026approval187d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

Sponsor: STRIDES PHARMA INTL. Form: TABLET. Route: ORAL

full page →DOXYCYCLINE HYCLATE →fda approvals ↗

Feb 6, 2026approval187d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

Sponsor: STRIDES PHARMA INTL. Form: TABLET. Route: ORAL

full page →DOXYCYCLINE HYCLATE →fda approvals ↗

Week of Feb 9, 2026

Feb 9, 2026approval184d agoREGLAN (METOCLOPRAMIDE HYDROCHLORIDE) — FDA approvalANI PHARMACEUTICALS INC

Sponsor: ANI PHARMS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 9, 2026approval

← prev

page 1 of 29

Week of Feb 2, 2026

Week of Feb 9, 2026